Clinical Trial Detail

NCT ID NCT02160015
Title Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Ibrutinib + Lenalidomide + Rituximab

Age Groups: senior adult

No variant requirements are available.